CN116688022A - Traditional Chinese medicine composition for treating toxoplasmosis and preparation method thereof - Google Patents
Traditional Chinese medicine composition for treating toxoplasmosis and preparation method thereof Download PDFInfo
- Publication number
- CN116688022A CN116688022A CN202310480009.6A CN202310480009A CN116688022A CN 116688022 A CN116688022 A CN 116688022A CN 202310480009 A CN202310480009 A CN 202310480009A CN 116688022 A CN116688022 A CN 116688022A
- Authority
- CN
- China
- Prior art keywords
- parts
- traditional chinese
- chinese medicine
- medicine composition
- allicin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 178
- 239000000203 mixture Substances 0.000 title claims abstract description 92
- 201000005485 Toxoplasmosis Diseases 0.000 title claims abstract description 61
- 238000002360 preparation method Methods 0.000 title claims abstract description 27
- JDLKFOPOAOFWQN-VIFPVBQESA-N Allicin Natural products C=CCS[S@](=O)CC=C JDLKFOPOAOFWQN-VIFPVBQESA-N 0.000 claims abstract description 46
- JDLKFOPOAOFWQN-UHFFFAOYSA-N allicin Chemical compound C=CCSS(=O)CC=C JDLKFOPOAOFWQN-UHFFFAOYSA-N 0.000 claims abstract description 46
- 235000010081 allicin Nutrition 0.000 claims abstract description 46
- 240000000233 Melia azedarach Species 0.000 claims abstract description 14
- 241000195954 Lycopodium clavatum Species 0.000 claims abstract description 13
- 241000196133 Dryopteris Species 0.000 claims abstract description 10
- 244000067505 Xanthium strumarium Species 0.000 claims abstract 3
- 239000007788 liquid Substances 0.000 claims description 41
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 40
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 33
- 238000001914 filtration Methods 0.000 claims description 29
- 238000002156 mixing Methods 0.000 claims description 29
- 240000002234 Allium sativum Species 0.000 claims description 27
- 235000004611 garlic Nutrition 0.000 claims description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 22
- 238000002791 soaking Methods 0.000 claims description 22
- 239000008367 deionised water Substances 0.000 claims description 20
- 229910021641 deionized water Inorganic materials 0.000 claims description 20
- 239000008187 granular material Substances 0.000 claims description 20
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 15
- 239000012046 mixed solvent Substances 0.000 claims description 15
- 235000002722 Dioscorea batatas Nutrition 0.000 claims description 12
- 235000006536 Dioscorea esculenta Nutrition 0.000 claims description 12
- 240000001811 Dioscorea oppositifolia Species 0.000 claims description 12
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 claims description 12
- 235000017784 Mespilus germanica Nutrition 0.000 claims description 12
- 244000182216 Mimusops elengi Species 0.000 claims description 12
- 235000000560 Mimusops elengi Nutrition 0.000 claims description 12
- 235000007837 Vangueria infausta Nutrition 0.000 claims description 12
- 241000928504 Centipeda minima Species 0.000 claims description 11
- 241000282326 Felis catus Species 0.000 claims description 11
- 244000303040 Glycyrrhiza glabra Species 0.000 claims description 11
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 11
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 11
- 235000011477 liquorice Nutrition 0.000 claims description 11
- 239000003208 petroleum Substances 0.000 claims description 11
- 230000008569 process Effects 0.000 claims description 11
- 230000002829 reductive effect Effects 0.000 claims description 11
- 239000006228 supernatant Substances 0.000 claims description 11
- 241000282472 Canis lupus familiaris Species 0.000 claims description 10
- 240000002948 Ophiopogon intermedius Species 0.000 claims description 10
- 238000005303 weighing Methods 0.000 claims description 10
- 239000006000 Garlic extract Substances 0.000 claims description 9
- 229920002472 Starch Polymers 0.000 claims description 9
- 235000016639 Syzygium aromaticum Nutrition 0.000 claims description 9
- 244000223014 Syzygium aromaticum Species 0.000 claims description 9
- 235000020706 garlic extract Nutrition 0.000 claims description 9
- 239000007787 solid Substances 0.000 claims description 9
- 235000019698 starch Nutrition 0.000 claims description 9
- 239000008107 starch Substances 0.000 claims description 9
- 241000222684 Grifola Species 0.000 claims description 7
- 238000004821 distillation Methods 0.000 claims description 6
- 238000001953 recrystallisation Methods 0.000 claims description 6
- 241000222640 Polyporus Species 0.000 claims description 4
- 238000005119 centrifugation Methods 0.000 claims description 4
- 238000002137 ultrasound extraction Methods 0.000 claims description 4
- 229920001353 Dextrin Polymers 0.000 claims description 3
- 239000004375 Dextrin Substances 0.000 claims description 3
- 235000019425 dextrin Nutrition 0.000 claims description 3
- 239000002131 composite material Substances 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims description 2
- 239000000706 filtrate Substances 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 241001633683 Centipeda <firmicute> Species 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 32
- 231100000331 toxic Toxicity 0.000 abstract description 10
- 230000002588 toxic effect Effects 0.000 abstract description 10
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 230000000052 comparative effect Effects 0.000 description 25
- 229940079593 drug Drugs 0.000 description 25
- 239000000243 solution Substances 0.000 description 18
- 241000699670 Mus sp. Species 0.000 description 13
- 241000223996 Toxoplasma Species 0.000 description 12
- 241001506766 Xanthium Species 0.000 description 11
- 230000002147 killing effect Effects 0.000 description 7
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 description 6
- 235000003097 Artemisia absinthium Nutrition 0.000 description 6
- 240000001851 Artemisia dracunculus Species 0.000 description 6
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 description 6
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 6
- 239000001138 artemisia absinthium Substances 0.000 description 6
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000011259 mixed solution Substances 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 241000721047 Danaus plexippus Species 0.000 description 4
- 244000115361 Dryopteris fragrans Species 0.000 description 4
- 235000005075 Dryopteris fragrans Nutrition 0.000 description 4
- 210000000683 abdominal cavity Anatomy 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 244000045947 parasite Species 0.000 description 4
- 241000282465 Canis Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 235000019658 bitter taste Nutrition 0.000 description 3
- 230000003071 parasitic effect Effects 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 229960002135 sulfadimidine Drugs 0.000 description 3
- ASWVTGNCAZCNNR-UHFFFAOYSA-N sulfamethazine Chemical compound CC1=CC(C)=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 ASWVTGNCAZCNNR-UHFFFAOYSA-N 0.000 description 3
- 235000019605 sweet taste sensations Nutrition 0.000 description 3
- 241000092668 Artemisia capillaris Species 0.000 description 2
- 235000008658 Artemisia capillaris Nutrition 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 241000282324 Felis Species 0.000 description 2
- 241000245654 Gladiolus Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 244000171085 Polyporus umbellatus Species 0.000 description 2
- 235000004837 Polyporus umbellatus Nutrition 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000607059 Solidago Species 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 210000000081 body of the sternum Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- WKSAUQYGYAYLPV-UHFFFAOYSA-N pyrimethamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1 WKSAUQYGYAYLPV-UHFFFAOYSA-N 0.000 description 2
- 229960000611 pyrimethamine Drugs 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 2
- 229960004306 sulfadiazine Drugs 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 235000001405 Artemisia annua Nutrition 0.000 description 1
- 240000000011 Artemisia annua Species 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 244000237986 Melia azadirachta Species 0.000 description 1
- 235000013500 Melia azadirachta Nutrition 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000037831 Polygonatum sibiricum Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 230000008175 fetal development Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000019633 pungent taste Nutrition 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 210000003812 trophozoite Anatomy 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
- A61K36/12—Filicopsida or Pteridopsida
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/483—Gleditsia (locust)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/58—Meliaceae (Chinaberry or Mahogany family), e.g. Azadirachta (neem)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8968—Ophiopogon (Lilyturf)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C381/00—Compounds containing carbon and sulfur and having functional groups not covered by groups C07C301/00 - C07C337/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the field of traditional Chinese medicine compositions, and particularly discloses a traditional Chinese medicine composition for treating toxoplasmosis as well as a preparation method and application thereof. The traditional Chinese medicine composition provided by the invention comprises the following components in parts by weight: 1-10 parts of dryopteris bicolor, 1-10 parts of allicin, 1-5 parts of herba artemisiae capillaries, 2-5 parts of chinaberry flowers, 1-5 parts of lycopodium clavatum, 1-4 parts of cocklebur and 1-4 parts of spina gleditsiae. The invention effectively solves the technical problems of large toxic and side effects and poor treatment effect of the traditional medicine for treating toxoplasmosis by utilizing the synergistic effect of the components, and the traditional Chinese medicine composition has safe components, small toxic and side effects and obvious effect for treating toxoplasmosis.
Description
Technical Field
The invention relates to the field of traditional Chinese medicine compositions, and in particular discloses a traditional Chinese medicine composition for treating toxoplasmosis and a preparation method thereof.
Background
Toxoplasmosis is an intracellular parasitic protozoal disease caused by toxoplasmosis just before, and toxoplasmosis is parasitic in all nucleated cells of animal organisms, flows along with blood, reaches organs such as brain, heart, fundus and the like, greatly reduces the immunity of a host, and is suffering from various diseases. With the increase of domestic pets, the pathogenic rate of dogs and cats infecting human bodies is greatly increased, and the method has great hidden danger to human health, wherein, toxoplasmosis of eyes and toxoplasmosis of brain are most common, especially pregnant women are extremely easy to infect, and the fetal development deformity is caused, so that the harm is extremely high.
In recent years, although great progress has been made in diagnosis, epidemiology and etiology, there is little effect in the treatment of toxoplasmosis, and no prophylactic or specific drug treatment has been available due to the complexity of toxoplasmosis life cycle, diversity of pathogenesis and differences in biological properties. At present, the most used medicines for treating toxoplasmosis are pyrimethamine and sulfadiazine or the combination of pyrimethamine and sulfadiazine, the treatment mechanism is mainly to inhibit trophozoite and control clinical symptoms, but the capsule of toxoplasmosis is ineffective, the toxoplasmosis is easy to relapse, the treatment period is long, the side effect of the medicines is large, some medicines are treated by antibiotics, such as azithromycin, clindamycin and the like, but the toxic side effect of the medicines is strong, the dosage is required to be strictly controlled, dermatitis is easy to cause even more, and the medicine is not suitable for long-term administration. Therefore, research and development of a drug with small toxic and side effects, which can effectively inhibit, expel or kill toxoplasma in animal cells and improve the living environment of the animal cells, is still a serious issue in current researches.
Disclosure of Invention
Aiming at the technical problems of large toxic and side effects and poor treatment effect of the traditional medicine for treating toxoplasmosis in the prior art, the invention provides the traditional Chinese medicine composition for treating toxoplasmosis and the preparation method thereof.
In order to further explain the technical scheme of the invention, the specific contents are as follows:
the invention provides a traditional Chinese medicine composition for treating toxoplasmosis, which comprises the following components in parts by mass: 1-10 parts of dryopteris bicolor, 1-10 parts of allicin, 1-5 parts of herba artemisiae capillaries, 2-5 parts of chinaberry flowers, 1-5 parts of lycopodium clavatum, 1-4 parts of cocklebur and 1-4 parts of spina gleditsiae.
Preferably, the traditional Chinese medicine composition for treating toxoplasmosis further comprises the following components in parts by mass: 1-5 parts of dwarf lilyturf tuber, 2-5 parts of centipeda minima, 1-5 parts of medlar, 0.5-2 parts of Polyporus, 1-4 parts of Chinese yam and 1-5 parts of liquorice.
Compared with the prior art, the traditional Chinese medicine composition for treating toxoplasmosis provided by the invention takes the two-color dryopteris fragrans and the garlicin as monarch drugs, has bitter taste, slightly cold nature, has the effects of killing parasites and sterilizing, has the effects of clearing away heat and toxic materials, inhibiting bacteria and cooling blood, can effectively expel and kill parasitic toxoplasmosis, and belongs to common and well-known pteridophytes in China, and the two-color dryopteris fragrans has safe components and lower cost; the allicin is used as a broad-spectrum antibacterial agent, has stronger antibacterial and anti-inflammatory effects, and can be combined with the two-color dryopteris fragrans to improve the performance of expelling and killing toxoplasma; the invention takes the capillary artemisia, chinaberry flower, common clubmoss herb, cocklebur fruit and spina gleditsiae as ministerial drugs, the capillary artemisia has bitter and pungent taste and slight cold nature, and can be used for assisting monarch drugs to kill toxoplasmosis; the chinaberry flower has the functions of clearing heat, eliminating dampness, killing parasites and relieving itching; herba Lycopodii has warm nature, and has effects of warming kidney, relieving pain, killing parasite, dredging channels and activating collaterals; the cocklebur is slightly bitter and slightly cold in nature, and has the effects of dispelling wind, dissipating heat, killing parasites, removing dampness, detoxifying and the like; the spina gleditsiae is warm in nature and pungent in taste, has the effects of detumescence, expelling pus and killing insects; in addition, the invention takes dwarf lilyturf tuber, centipeda minima, medlar, polyporus and Chinese yam as adjuvant drugs, wherein the dwarf lilyturf tuber has sweet and slightly bitter taste and slightly cold nature and has the effects of nourishing yin and moistening lung, benefiting stomach and promoting fluid production, resisting myocardial ischemia, resisting arrhythmia and tumor and the like; centipeda minima has the effects of relieving depression, eliminating sore and swelling, sterilizing and the like; the medlar has sweet taste and mild nature, and has the effects of nourishing liver and tonifying kidney, replenishing vital essence and improving eyesight, nourishing and strengthening the like; polyporus umbellatus is sweet in taste and neutral in nature, and has effects of relieving fever, removing dampness, promoting resuscitation and inducing diuresis; the Chinese yam has sweet taste, warm nature and flat nature, and has the effects of tonifying middle-jiao, invigorating qi, growing muscles, strengthening yin and the like; the invention also takes the liquorice as a guiding drug, has sweet taste and flat nature, and has the effects of clearing heat and detoxicating, dredging nine orifices, benefiting hundred vessels, replenishing essence and nourishing qi, and tonifying spleen and moistening lung. The invention takes specific traditional Chinese medicines as monarch medicines, ministerial medicines, adjuvant medicines and conductant medicines, utilizes the synergistic effect of the components to promote the efficacy of the monarch medicines in expelling and killing toxoplasmosis, has small toxic and side effects, supplements middle-jiao and qi, has safe components, obvious effect and lower cost, and provides a good solution for treating toxoplasmosis.
Preferably, 3-8 parts of dryopteris bipinnata, 3-9 parts of allicin, 2-4 parts of virgate wormwood herb, 2-4 parts of chinaberry flower, 2-4 parts of lycopodium clavatum, 2-3 parts of cocklebur, 2-3 parts of spina gleditsiae, 3-4 parts of dwarf lilyturf tuber, 3-4 parts of centipeda minima, 2-4 parts of medlar, 1-1.5 parts of grifola, 2-3 parts of Chinese yam and 3-4 parts of liquorice.
Preferably, the extraction method of the allicin comprises the following steps:
step a, crushing clean garlic cloves to obtain mashed garlic;
step b, adding the mashed garlic into acetic acid solution, soaking, filtering, taking a solid filtrate, adding a mixed solvent of petroleum ether and ethanol, performing ultrasonic extraction, centrifuging, and taking a supernatant to obtain an allicin extract;
and c, concentrating the garlic extract, and recrystallizing to obtain the allicin.
Preferably, in the step b, the mass percentage of the acetic acid solution is 10% -15%.
Preferably, in the step b, the soaking time is 10-30 h.
Preferably, in the step b, the volume ratio of petroleum ether to ethanol in the mixed solvent is 1:1.5-2.5.
Preferably, in the step b, the frequency of the ultrasonic wave is 30kHz-45kHz, and the ultrasonic wave time is 20min-40min.
Preferably, in the step b, the rotation speed of the centrifugation is 400rpm-800rpm, and the centrifugation time is 15min-30min.
Preferably, in the step c, the concentration is reduced pressure distillation, the vacuum degree of distillation is 0.07MPa-0.085MPa, and the temperature of distillation is 30-50 ℃.
Preferably, in the step c, the solvent for recrystallization is a mixed solvent of acetone and ethanol with the volume ratio of 2-4:0.7-1.4, the recrystallization temperature is 25-45 ℃, and the recrystallization time is 10-20 h.
The second aspect of the invention provides a preparation method of the traditional Chinese medicine composition for treating toxoplasmosis, which at least comprises the following steps:
firstly, weighing the components according to a designed proportion, uniformly mixing the weighed components except allicin, adding the components into deionized water for soaking, decocting at 95-110 ℃, and filtering to obtain a first liquid medicine and medicinal residues;
adding water into the dregs, decocting at 100-110 ℃, and filtering to obtain a second liquid medicine;
step three, uniformly mixing the first liquid medicine and the allicin, decocting at 100-110 ℃, and adding the second mixed liquid medicine for 3-4 times in the decoction process to obtain the traditional Chinese medicine composition.
Preferably, in the first step, the total mass ratio of the deionized water to the composition is 30-50:1.
Preferably, in the first step, the soaking time is 0.5h-3h.
Preferably, in the first step, the decoction time is 0.5h-1.5h.
Preferably, in the second step, the mass ratio of the dregs to the deionized water is 1:20-40.
Preferably, in the second step, the decoction time is 30min-60min.
Preferably, in the third step, the decoction time is 20min-30min.
The third aspect of the invention provides application of the traditional Chinese medicine composition for treating toxoplasmosis in treating canine and feline toxoplasmosis.
The fourth aspect of the invention provides a traditional Chinese medicine preparation for treating toxoplasmosis, which comprises the traditional Chinese medicine composition for treating toxoplasmosis.
Preferably, the traditional Chinese medicine preparation is in the form of granules.
The fifth aspect of the invention provides a preparation method of the traditional Chinese medicine preparation for treating toxoplasmosis, which comprises the following steps: mixing the traditional Chinese medicine composition with starch or dextrin according to the mass ratio of 1:10-20, and granulating to obtain the traditional Chinese medicine composite granules.
Aiming at the treatment of toxoplasmosis, the invention provides a traditional Chinese medicine composition for treating toxoplasmosis, which is prepared by compatibility of components, effectively dispels and kills toxoplasmosis, has safe components, small toxic and side effects and obvious toxoplasmosis treatment effect, can be prepared into a granular medicament, is convenient for dogs and cats to feed, and is simple and convenient to operate.
Detailed Description
The following description of the technical solutions in the embodiments of the present invention will be clear and complete, and it is obvious that the described embodiments are only some embodiments of the present invention, but not all embodiments. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.
Example 1
The embodiment provides a traditional Chinese medicine composition for treating toxoplasmosis, which comprises the following specific contents:
the traditional Chinese medicine composition comprises the following components in parts by weight: 7g of dryopteris bicolor, 7g of garlicin, 3g of virgate wormwood herb, 3g of chinaberry flower, 2g of lycopodium clavatum, 2g of cocklebur, 3g of spina gleditsiae, 3g of dwarf lilyturf tuber, 3g of centipeda minima, 3g of medlar, 1g of grifola, 2g of Chinese yam and 3g of liquorice.
The traditional Chinese medicine composition is a traditional Chinese medicine composition granule, and the specific preparation method is as follows:
crushing clean garlic cloves to obtain mashed garlic; soaking the mashed garlic in an acetic acid solution with the mass percent of 10% for 20 hours, filtering, taking a solid filter, adding a mixed solution of petroleum ether and ethanol with the volume ratio of 1:2, ultrasonically extracting for 30 minutes at the frequency of 40kHz, centrifuging for 20 minutes at the rotating speed of 550r/min, and taking a supernatant to obtain an allicin extract;
distilling the garlic extract under reduced pressure at 40 ℃ and minus 0.08MPa, recrystallizing the concentrated solution with a mixed solvent of acetone and ethanol in a volume ratio of 3:1 at 35 ℃ for 10 hours to obtain allicin;
weighing the components according to the designed proportion, uniformly mixing the weighed components except allicin, adding 1500mL of deionized water for soaking for 2 hours, decocting for 1.5 hours at 100 ℃, and filtering to obtain a first liquid medicine and medicine residues;
adding deionized water into the dregs according to the mass ratio of 30:1, decocting for 35min at 100 ℃, and filtering to obtain a second liquid medicine;
step five, uniformly mixing the first liquid medicine and the allicin, and decocting for 25min at 50 ℃, wherein the second mixed liquid medicine is added for 4 times in the decoction process to obtain the traditional Chinese medicine composition;
and step six, uniformly mixing the traditional Chinese medicine composition with starch according to the mass ratio of 1:20, and granulating to obtain the traditional Chinese medicine composition granules.
Example 2
The embodiment provides a traditional Chinese medicine composition for treating toxoplasmosis, which comprises the following specific contents:
the traditional Chinese medicine composition comprises the following components in parts by weight: 7g of dryopteris bicolor, 7g of garlicin, 3g of virgate wormwood herb, 3g of chinaberry flower, 2g of lycopodium clavatum, 2g of cocklebur, 3g of spina gleditsiae, 3g of dwarf lilyturf tuber, 3g of centipeda minima, 3g of medlar, 1g of grifola, 2g of Chinese yam and 3g of liquorice.
The traditional Chinese medicine composition is a traditional Chinese medicine composition granule, and the specific preparation method is as follows:
crushing clean garlic cloves to obtain mashed garlic; soaking the mashed garlic in acetic acid solution with the mass percent of 15% for 20 hours, filtering, taking a solid filter, adding a mixed solvent of petroleum ether and ethanol with the volume ratio of 1:2, ultrasonically extracting for 30 minutes at the frequency of 45kHz, centrifuging for 20 minutes at the rotating speed of 550r/min, and taking a supernatant to obtain an allicin extract;
distilling the garlic extract under reduced pressure at 40 ℃ and minus 0.08MPa, recrystallizing the concentrated solution with a mixed solvent of acetone and ethanol in a volume ratio of 3:1 at 40 ℃ for 10 hours to obtain allicin;
weighing the components according to the designed proportion, uniformly mixing the weighed components except allicin, adding 1400mL of deionized water for soaking for 2 hours, decocting for 1.5 hours at 105 ℃, and filtering to obtain a first liquid medicine and medicine residues;
adding deionized water into the dregs according to the mass ratio of 30:1, decocting for 35min at 100 ℃, and filtering to obtain a second liquid medicine;
step five, uniformly mixing the first liquid medicine and the allicin, and decocting for 25min at 50 ℃, wherein the second mixed liquid medicine is added for 4 times in the decoction process to obtain the traditional Chinese medicine composition;
and step six, uniformly mixing the traditional Chinese medicine composition with dextrin according to the mass ratio of 1:20, and granulating to obtain the traditional Chinese medicine composition granules.
Example 3
The embodiment provides a traditional Chinese medicine composition for treating toxoplasmosis, which comprises the following specific contents:
the traditional Chinese medicine composition comprises the following components in parts by weight: 7g of dryopteris bicolor, 7g of garlicin, 3g of virgate wormwood herb, 3g of chinaberry flower, 2g of lycopodium clavatum, 2g of cocklebur and 3g of spina gleditsiae.
The traditional Chinese medicine composition is a traditional Chinese medicine composition granule, and the specific preparation method is as follows:
crushing clean garlic cloves to obtain mashed garlic; soaking the mashed garlic in acetic acid solution with the mass percentage of 12% for 30 hours, filtering, taking a solid filter, adding a mixed solution of petroleum ether and ethanol with the volume ratio of 1:2.5, ultrasonically extracting for 30 minutes at the frequency of 35kHz, centrifuging for 20 minutes at the rotating speed of 550r/min, and taking a supernatant to obtain an allicin extract;
distilling the garlic extract under reduced pressure at 40 ℃ below zero and minus 0.075MPa, recrystallizing the concentrated solution with a mixed solvent of acetone and ethanol in a volume ratio of 3:1.2 at 45 ℃ for 10h to obtain allicin;
weighing the components according to the designed proportion, uniformly mixing the weighed components except allicin, adding 1450mL of deionized water for soaking for 2 hours, decocting for 1.5 hours at 100 ℃, and filtering to obtain a first liquid medicine and medicine residues;
adding deionized water into the dregs according to the mass ratio of 30:1, decocting for 35min at 100 ℃, and filtering to obtain a second liquid medicine;
step five, uniformly mixing the first liquid medicine and the allicin, and decocting for 25min at 50 ℃, wherein the second mixed liquid medicine is added for 4 times in the decoction process to obtain the traditional Chinese medicine composition;
and step six, uniformly mixing the traditional Chinese medicine composition with starch according to the mass ratio of 1:15, and granulating to obtain the traditional Chinese medicine composition granules.
Comparative example 1
This comparative example differs from example 1 in that the substitution of the two-color dryopteris forbesii with semen Torreyae, the other components and the preparation method are unchanged.
The comparative example provides a traditional Chinese medicine composition for treating toxoplasmosis, which comprises the following specific contents:
the traditional Chinese medicine composition comprises the following components in parts by weight: 7g of semen Torreyae, 7g of garlicin, 3g of herba Artemisiae Scopariae, 3g of chinaberry flower, 2g of herba Lycopodii, 2g of herba Xanthii, 3g of spina Gleditsiae, 3g of radix Ophiopogonis, 3g of herba Centipedae, 3g of fructus Lycii, 1g of Polyporus, 2g of rhizoma Dioscoreae and 3g of Glycyrrhrizae radix.
The traditional Chinese medicine composition is a traditional Chinese medicine composition granule, and the specific preparation method is as follows:
crushing clean garlic cloves to obtain mashed garlic; soaking the mashed garlic in an acetic acid solution with the mass percent of 10% for 20 hours, filtering, taking a solid filter, adding a mixed solution of petroleum ether and ethanol with the volume ratio of 1:2, ultrasonically extracting for 30 minutes at the frequency of 40kHz, centrifuging for 20 minutes at the rotating speed of 550r/min, and taking a supernatant to obtain an allicin extract;
distilling the garlic extract under reduced pressure at 40 ℃ and minus 0.08MPa, recrystallizing the concentrated solution with a mixed solvent of acetone and ethanol in a volume ratio of 3:1 at 35 ℃ for 10 hours to obtain allicin;
weighing the components according to the designed proportion, uniformly mixing the weighed components except allicin, adding 1500mL of deionized water for soaking for 2 hours, decocting for 1.5 hours at 100 ℃, and filtering to obtain a first liquid medicine and medicine residues;
adding deionized water into the dregs according to the mass ratio of 30:1, decocting for 35min at 100 ℃, and filtering to obtain a second liquid medicine;
step five, uniformly mixing the first liquid medicine and the allicin, and decocting for 25min at 50 ℃, wherein the second mixed liquid medicine is added for 4 times in the decoction process to obtain the traditional Chinese medicine composition;
step six, uniformly mixing the traditional Chinese medicine composition with starch according to the mass ratio of 1:10-20, and granulating to obtain the traditional Chinese medicine composition granules.
Comparative example 2
The comparative example differs from example 1 in that allicin was replaced with gladiolus, and other components and preparation methods were unchanged.
The comparative example provides a traditional Chinese medicine composition for treating toxoplasmosis, which comprises the following specific contents:
the traditional Chinese medicine composition comprises the following components in parts by weight: 7g of dryopteris bipinnata, 7g of gladiolus, 3g of virgate wormwood herb, 3g of chinaberry flower, 2g of lycopodium clavatum, 2g of cocklebur, 3g of spina gleditsiae, 3g of dwarf lilyturf tuber, 3g of centipeda minima, 3g of medlar, 1g of polyporus umbellatus, 2g of Chinese yam and 3g of liquorice.
The traditional Chinese medicine composition is a traditional Chinese medicine composition granule, and the specific preparation method is as follows:
firstly, weighing the components according to a designed proportion, uniformly mixing the weighed components, adding 1500mL of deionized water for soaking for 2 hours, decocting for 1.5 hours at 100 ℃, and filtering to obtain a first liquid medicine and medicine residues;
adding deionized water into the dregs according to the mass ratio of 30:1, decocting for 35min at 100 ℃, and filtering to obtain a second liquid medicine;
step three, decocting the first liquid medicine at 50 ℃ for 25min, and adding the second mixed liquid medicine into the decoction for 4 times in the decoction process to obtain a traditional Chinese medicine composition;
and fourthly, uniformly mixing the traditional Chinese medicine composition with starch according to the mass ratio of 1:10-20, and granulating to obtain the traditional Chinese medicine composition granules.
Comparative example 3
The comparative example differs from example 1 in that the two-color dryopteris fragrans is replaced with Polygonatum sibiricum, and the other components and preparation methods are unchanged.
The comparative example provides a traditional Chinese medicine composition for treating toxoplasmosis, which comprises the following specific contents:
the traditional Chinese medicine composition comprises the following components in parts by weight: 7g of rhizoma polygonati, 7g of garlicin, 3g of virgate wormwood herb, 3g of chinaberry flower, 2g of lycopodium clavatum, 2g of cocklebur, 3g of spina gleditsiae, 3g of dwarf lilyturf tuber, 3g of centipeda minima, 3g of medlar, 1g of grifola, 2g of Chinese yam and 3g of liquorice.
The traditional Chinese medicine composition is a traditional Chinese medicine composition granule, and the specific preparation method is as follows:
crushing clean garlic cloves to obtain mashed garlic; soaking the mashed garlic in an acetic acid solution with the mass percent of 10% for 20 hours, filtering, taking a solid filter, adding a mixed solvent of petroleum ether and ethanol with the volume ratio of 1:2, ultrasonically extracting for 30 minutes at the frequency of 40kHz, centrifuging for 20 minutes at the rotating speed of 550r/min, and taking a supernatant to obtain an allicin extract;
distilling the garlic extract under reduced pressure at 40 ℃ and minus 0.08MPa, recrystallizing the concentrated solution with a mixed solvent of acetone and ethanol in a volume ratio of 3:1 at 35 ℃ for 10 hours to obtain allicin;
weighing the components according to the designed proportion, uniformly mixing the weighed components except allicin, adding 1500mL of deionized water for soaking for 2 hours, decocting for 1.5 hours at 100 ℃, and filtering to obtain a first liquid medicine and medicine residues;
adding deionized water into the dregs according to the mass ratio of 30:1, decocting for 35min at 100 ℃, and filtering to obtain a second liquid medicine;
step five, uniformly mixing the first liquid medicine and the allicin, and decocting for 25min at 50 ℃, wherein the second mixed liquid medicine is added for 4 times in the decoction process to obtain the traditional Chinese medicine composition;
step six, uniformly mixing the traditional Chinese medicine composition with starch according to the mass ratio of 1:10-20, and granulating to obtain the traditional Chinese medicine composition granules.
Comparative example 4
This comparative example differs from example 1 in that the herba Artemisiae Scopariae was replaced with herba Artemisiae Annuae, and the other components and preparation methods were unchanged.
The comparative example provides a traditional Chinese medicine composition for treating toxoplasmosis, which comprises the following specific contents:
the traditional Chinese medicine composition comprises the following components in parts by weight: 7g of rhizoma polygonati, 7g of allicin, 3g of sweet wormwood, 3g of chinaberry flower, 2g of lycopodium clavatum, 2g of cocklebur, 3g of spina gleditsiae, 3g of dwarf lilyturf tuber, 3g of centipeda minima, 3g of medlar, 1g of grifola, 2g of Chinese yam and 3g of liquorice.
The traditional Chinese medicine composition is a traditional Chinese medicine composition granule, and the specific preparation method is as follows:
crushing clean garlic cloves to obtain mashed garlic; soaking the mashed garlic in an acetic acid solution with the mass percent of 10% for 20 hours, filtering, taking a solid filter, adding a mixed solution of petroleum ether and ethanol with the volume ratio of 1:2, ultrasonically extracting for 30 minutes at the frequency of 40kHz, centrifuging for 20 minutes at the rotating speed of 550r/min, and taking a supernatant to obtain an allicin extract;
distilling the garlic extract under reduced pressure at 40 ℃ and minus 0.08MPa, recrystallizing the concentrated solution with a mixed solvent of acetone and ethanol in a volume ratio of 3:1 at 35 ℃ for 10 hours to obtain allicin;
weighing the components according to the designed proportion, uniformly mixing the weighed components except allicin, adding 1500mL of deionized water for soaking for 2 hours, decocting for 1.5 hours at 100 ℃, and filtering to obtain a first liquid medicine and medicine residues;
adding deionized water into the dregs according to the mass ratio of 30:1, decocting for 35min at 100 ℃, and filtering to obtain a second liquid medicine;
step five, uniformly mixing the first liquid medicine and the allicin, and decocting for 25min at 50 ℃, wherein the second mixed liquid medicine is added for 4 times in the decoction process to obtain the traditional Chinese medicine composition;
step six, uniformly mixing the traditional Chinese medicine composition with starch according to the mass ratio of 1:10-20, and granulating to obtain the traditional Chinese medicine composition granules.
Comparative example 5
The comparative example differs from example 1 in that the neem flower is replaced by solidago, and the other components and preparation methods are unchanged.
The comparative example provides a traditional Chinese medicine composition for treating toxoplasmosis, which comprises the following specific contents:
the traditional Chinese medicine composition comprises the following components in parts by weight: 7g of rhizoma polygonati, 7g of garlicin, 3g of herba artemisiae scopariae, 3g of solidago, 2g of lycopodium clavatum, 2g of cocklebur, 3g of spina gleditsiae, 3g of radix ophiopogonis, 3g of centipeda minima, 3g of medlar, 1g of grifola, 2g of Chinese yam and 3g of liquorice.
The traditional Chinese medicine composition is a traditional Chinese medicine composition granule, and the specific preparation method is as follows:
crushing clean garlic cloves to obtain mashed garlic; soaking the mashed garlic in an acetic acid solution with the mass percent of 10% for 20 hours, filtering, taking a solid filter, adding a mixed solution of petroleum ether and ethanol with the volume ratio of 1:2, ultrasonically extracting for 30 minutes at the frequency of 40kHz, centrifuging for 20 minutes at the rotating speed of 550r/min, and taking a supernatant to obtain an allicin extract;
distilling the garlic extract under reduced pressure at 40 ℃ and minus 0.08MPa, recrystallizing the concentrated solution with a mixed solvent of acetone and ethanol in a volume ratio of 3:1 at 35 ℃ for 10 hours to obtain allicin;
weighing the components according to the designed proportion, uniformly mixing the weighed components except allicin, adding 1500mL of deionized water for soaking for 2 hours, decocting for 1.5 hours at 100 ℃, and filtering to obtain a first liquid medicine and medicine residues;
adding deionized water into the dregs according to the mass ratio of 30:1, decocting for 35min at 100 ℃, and filtering to obtain a second liquid medicine;
step five, uniformly mixing the first liquid medicine and the allicin, and decocting for 25min at 50 ℃, wherein the second mixed liquid medicine is added for 4 times in the decoction process to obtain the traditional Chinese medicine composition;
step six, uniformly mixing the traditional Chinese medicine composition with starch according to the mass ratio of 1:10-20, and granulating to obtain the traditional Chinese medicine composition granules.
Comparative example 6
The comparative example provides a commercial sulfadimidine tablet (specification: 500 mg/tablet) for animals.
In order to further illustrate the technical effects of the invention, the invention carries out toxoplasma treatment tests, and the specific contents are as follows:
1. animal test:
and a, taking fresh tissues such as cat liver, spleen, heart blood, lymph nodes and the like which die from complications caused by toxoplasma, grinding, and then adding 10 times of physiological saline for double antibody treatment. Standing at room temperature for 1h, shaking, centrifuging at a speed of 100r/min, and inoculating supernatant to a test mouse. 20 mice are equally divided into A, B groups, wherein, group A is inoculated with 1mL of supernatant liquid in each abdominal cavity, group B is a blank control group, and each abdominal cavity is inoculated with 1mL of physiological saline;
step b, observing every day after inoculation, and leading 4 mice in the group A to be ill at 3d, 9 mice to be ill after two weeks, and 1 mouse to die; group B had no significant change.
And c, performing microscopic examination on ascites of the mice with the disease, finding that typical toxoplasma exists and counting the number of toxoplasma bodies.
Step d, dividing the mice with the disease into two groups, wherein one group is treated by the traditional Chinese medicine composition particles provided by the embodiment 1 of the invention, the traditional Chinese medicine composition particles are dissolved in normal saline, and the dosage of the traditional Chinese medicine composition particles is 200 mg/kg according to the weight of the mice, and the mice are infused with stomach twice a day; one group of the commercially available western medicines, namely the sulfamethazine tablet, is treated, the sulfamethazine tablet is dissolved in normal saline, the administration dosage is 200 mg/kg according to the weight of the mice, the mice are subjected to stomach infusion, and the number of the mice which are subjected to laparoscopic technology is respectively taken from 3d, 5d, 7d, 10d, 15d and 20d twice a day, and the results are shown in table 1.
Table 1 comparison of results of traditional Chinese medicine treatment and Western medicine treatment on sick mice
From the results shown in Table 1, it can be seen that the reduction rates of the numbers of toxoplasma bodies in the abdominal cavities of the mice treated by the traditional Chinese medicine provided by the invention are 25.8%, 49.9%, 60.7%, 66.4%, 91.51% and 98.9% in terms of 3d, 5d, 7d, 10d, 15d and 20 d; the reduction rate of toxoplasma in the abdominal cavity of the western medicine treated mice is 31.4%, 43.1%, 51.8%, 56.3%, 81.5% and 95.5% in the number of toxoplasma in the 3 rd, 5 th, 7 th, 10 th, 15 th and 20 th d.
2. The invention compares the clinical treatment results of canine and feline toxoplasmosis
The medicines provided by the examples and the comparative examples are used for treating the sick dogs, the dosage of the medicines is 200 mg/kg according to the weight of the dogs, the medicines are taken twice a day after being dissolved in water, and the medicines are used for 15 days continuously, and the specific results are shown in Table 2.
Cure standard: the secretion in the diseased eyes of the dogs is obviously reduced, the spirit is recovered to be normal, symptoms such as cough, vomit, diarrhea and the like are avoided, the dogs actively eat, the feces are normal, blood is drawn for toxoplasma antibody detection, and if the dogs are positive, the dogs are cured.
TABLE 2 clinical treatment results of canine toxoplasmosis
| Group of | Number of diseases (Only) | Cure number (only) | Number of deaths (only) | Cure rate (%) |
| Example 1 | 212 | 197 | 15 | 92.9 |
| Example 2 | 187 | 169 | 18 | 90.3 |
| Example 3 | 195 | 175 | 20 | 89.7 |
| Comparative example 1 | 182 | 154 | 28 | 84.6 |
| Comparative example 2 | 176 | 143 | 33 | 81.2 |
| Comparative example 3 | 148 | 121 | 27 | 81.7 |
| Comparative example 4 | 158 | 124 | 34 | 78.5 |
| Comparative example 5 | 137 | 109 | 28 | 79.5 |
| Comparative example 6 | 179 | 157 | 22 | 87.7 |
The medicines provided by the examples and the comparative examples are used for treating diseased cats, the dosage of the medicines is 200 mg/kg according to the weight of the cats, the medicines are taken twice a day after being dissolved in water, and the medicines are taken for 15 days continuously, and the specific results are shown in Table 3.
Cure standard: the secretion in the diseased cat eye is obviously reduced, the body temperature is recovered to be normal, the spirit is recovered to be normal, diarrhea and vomiting are avoided, and the cat eye is actively fed, and toxoplasma test paper is adopted to test whether the cat feces are cured or not.
TABLE 3 clinical treatment results of Toxoplasma cat
According to the table 2, the traditional Chinese medicine composition particles provided by the embodiment of the invention have good effect and cure rate higher than 89% when used for treating diseased dogs. According to the table 3, the traditional Chinese medicine composition particles provided by the embodiment of the invention are used for treating diseased cats, and have good effects and cure rate higher than 89%.
In conclusion, the traditional Chinese medicine composition for treating toxoplasmosis provided by the invention has the advantages of safe components, small toxic and side effects and remarkable toxoplasmosis treatment effect, and the technical problems of large toxic and side effects and poor treatment effect of medicines in the prior art in the toxoplasmosis treatment process are effectively solved.
The foregoing description of the preferred embodiments of the invention is not intended to be limiting, but rather is intended to cover all modifications, equivalents, or alternatives falling within the spirit and principles of the invention.
Claims (10)
1. A traditional Chinese medicine composition for treating toxoplasmosis is characterized in that: comprises the following components in parts by weight: 1-10 parts of dryopteris bicolor, 1-10 parts of allicin, 1-5 parts of herba artemisiae capillaries, 2-5 parts of chinaberry flowers, 1-5 parts of lycopodium clavatum, 1-4 parts of cocklebur and 1-4 parts of spina gleditsiae.
2. The traditional Chinese medicine composition for treating toxoplasmosis according to claim 1, wherein: the composition also comprises the following components in mass: 1-5 parts of dwarf lilyturf tuber, 2-5 parts of centipeda minima, 1-5 parts of medlar, 0.5-2 parts of Polyporus, 1-4 parts of Chinese yam and 1-5 parts of liquorice.
3. The traditional Chinese medicine composition for treating toxoplasmosis according to claim 1, which is characterized by comprising the following components in parts by weight: 3-8 parts of dryopteris bicolor, 3-9 parts of allicin, 2-4 parts of herba artemisiae capillaries, 2-4 parts of chinaberry flowers, 2-4 parts of lycopodium clavatum, 2-3 parts of cocklebur, 2-3 parts of spina gleditsiae, 3-4 parts of radix ophiopogonis, 3-4 parts of centipeda, 2-4 parts of medlar, 1-1.5 parts of grifola, 2-3 parts of Chinese yam and 3-4 parts of liquorice.
4. The traditional Chinese medicine composition for treating toxoplasmosis according to claim 1, wherein: the extraction method of the allicin comprises the following steps:
step a, crushing clean garlic cloves to obtain mashed garlic;
step b, adding the mashed garlic into acetic acid solution, soaking, filtering, taking a solid filtrate, adding a mixed solvent of petroleum ether and ethanol, performing ultrasonic extraction, centrifuging, and taking a supernatant to obtain an allicin extract;
and c, concentrating the garlic extract, and recrystallizing to obtain the allicin.
5. The traditional Chinese medicine composition for treating toxoplasmosis according to claim 4, wherein: in the step b, the mass percentage of the acetic acid solution is 10% -15%; and/or
In the step b, the soaking time is 10-30 hours; and/or
In the step b, the volume ratio of petroleum ether to ethanol in the mixed solvent is 1:1.5-2.5; and/or
In the step b, the frequency of ultrasonic extraction is 30kHz-45kHz, and the time of ultrasonic extraction is 20-40 min; and/or
In the step b, the rotational speed of the centrifugation is 400rpm-800rpm, and the centrifugation time is 15min-30min; and/or
In the step c, the concentration is reduced pressure distillation, the vacuum degree of distillation is 0.07MPa-0.085MPa, and the distillation temperature is 30-50 ℃; and/or
In the step c, the solvent for recrystallization is a mixed solvent of acetone and ethanol with the volume ratio of 2-4:0.7-1.4, the recrystallization temperature is 25-45 ℃, and the recrystallization time is 10-20 h.
6. The method for preparing the traditional Chinese medicine composition for treating toxoplasmosis according to any one of claims 1 to 5, which is characterized in that: at least comprises the following steps:
firstly, weighing the components according to a designed proportion, uniformly mixing the weighed components except allicin, adding the components into deionized water for soaking, decocting at 95-110 ℃, and filtering to obtain a first liquid medicine and medicinal residues;
adding water into the dregs, decocting at 100-110 ℃, and filtering to obtain a second liquid medicine;
step three, uniformly mixing the first liquid medicine and the allicin, decocting at 100-110 ℃, and adding the second mixed liquid medicine for 3-4 times in the decoction process to obtain the traditional Chinese medicine composition.
7. Use of the traditional Chinese medicine composition for treating toxoplasmosis according to any one of claims 1 to 5 for treating toxoplasmosis in dogs and cats.
8. A Chinese medicinal preparation for treating toxoplasmosis, which is characterized by comprising the Chinese medicinal composition for treating toxoplasmosis according to any one of claims 1 to 5.
9. The traditional Chinese medicine preparation for treating toxoplasmosis according to claim 8, wherein the dosage form of the traditional Chinese medicine preparation is a granule.
10. The method for preparing the traditional Chinese medicine preparation for treating toxoplasmosis according to claim 9, which is characterized in that: the method comprises the following steps: mixing the traditional Chinese medicine composition for treating toxoplasmosis with starch or dextrin according to the mass ratio of 1:10-20, granulating, and obtaining the traditional Chinese medicine composite granules.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310480009.6A CN116688022B (en) | 2023-04-28 | 2023-04-28 | Traditional Chinese medicine composition for treating toxoplasmosis and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310480009.6A CN116688022B (en) | 2023-04-28 | 2023-04-28 | Traditional Chinese medicine composition for treating toxoplasmosis and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116688022A true CN116688022A (en) | 2023-09-05 |
| CN116688022B CN116688022B (en) | 2024-06-04 |
Family
ID=87831877
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310480009.6A Active CN116688022B (en) | 2023-04-28 | 2023-04-28 | Traditional Chinese medicine composition for treating toxoplasmosis and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116688022B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110051808A (en) * | 2019-05-15 | 2019-07-26 | 陈云志 | For treating the Chinese medicine composition of toxoplasmosis |
| CN110585381A (en) * | 2019-09-27 | 2019-12-20 | 山东佳硒雅生物有限公司 | Medicinal and edible composition for expelling toxoplasma gondii and preparation method thereof |
-
2023
- 2023-04-28 CN CN202310480009.6A patent/CN116688022B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110051808A (en) * | 2019-05-15 | 2019-07-26 | 陈云志 | For treating the Chinese medicine composition of toxoplasmosis |
| CN110585381A (en) * | 2019-09-27 | 2019-12-20 | 山东佳硒雅生物有限公司 | Medicinal and edible composition for expelling toxoplasma gondii and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 陈光等: "中药大蒜素体外抗弓形虫效应及其机制的研究", vol. 21, no. 09, 30 September 2009 (2009-09-30), pages 812 - 821 * |
| 顾伟明: "中草药和除害防病", 上海中医药杂志, no. 06, 30 June 1981 (1981-06-30), pages 45 - 46 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116688022B (en) | 2024-06-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102048933B (en) | Chinese medicinal composition for treating infantile diarrhea and preparation method thereof | |
| CN102198262B (en) | Chinese medicine preparation for treating infant rotavirus enteritis and preparation method thereof | |
| CN104799003A (en) | Compound feed for 10-30-day-old piglets and preparing method thereof | |
| CN102772781A (en) | Traditional Chinese medicine preparation for treating chronic colitis and preparation method thereof | |
| CN103239651B (en) | Traditional Chinese medicine for treating subclinical mastitis for dairy cow | |
| CN102847021B (en) | Enema for treating ulcerative colitis and preparation method thereof | |
| CN100352463C (en) | Compound Chinese medicine for treating child diarrhea and its preparation method | |
| CN104840695A (en) | Medicine combination for treating white scour of piglet and preparation method thereof | |
| CN103920027A (en) | Medicament for treating acute jaundice hepatitis B and preparation method thereof | |
| CN116688022B (en) | Traditional Chinese medicine composition for treating toxoplasmosis and preparation method thereof | |
| CN103652490B (en) | Pig feed for treating blue-eared pig disease and preparation method thereof | |
| CN109432287B (en) | Traditional Chinese medicine oral liquid for preventing and treating excessive heat syndrome of poultry qi system and preparation method thereof | |
| CN103861007B (en) | A kind of Chinese herbal compound preparation for the treatment of chicken diarrhea | |
| CN103417653B (en) | Veterinary-use compound pure Chinese herbal medicine for treating coccidium and preparation method of oral liquid of same | |
| CN103007145B (en) | Traditional Chinese medicine composition for treating children rotavirus enteritis and preparation method of composition | |
| CN105250552A (en) | Pharmaceutical preparation used for treating acute gastroenteritis | |
| CN104352582A (en) | Medicine for preventing and treating colibacillosis of chickens and preparation method thereof | |
| CN104825784B (en) | A kind of Chinese medicine composition with anti-gastric cancer activity and its preparation method and application | |
| CN103690771B (en) | Be used for the treatment of medicine of lamb colibacillosis and preparation method thereof | |
| CN102793869A (en) | Traditional Chinese medicine composition for controlling porcine viral diseases and preparation method thereof | |
| CN104840716B (en) | Traditional Chinese medicine compound composition with anti-breast cancer activity and its preparation method and application | |
| CN116036174B (en) | Medicine for treating pulmonary nodules and preparation method thereof | |
| CN106943554A (en) | A kind of Chinese medicine composition for being used to treat chordapsus | |
| CN106729589A (en) | Treat the Chinese medicine preparation and preparation method of transmissible gastroenteritis of swine | |
| CN106074900A (en) | A kind of Chinese medicine composition of adjuvant treatment of acute pulmonary abscess |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |